Selective oestrogen receptor downregulator

Same author

How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK family history risk and prevention clinic.

BMC cancer·2026

Same author

Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancer.

Journal of medical genetics·2025

Same author

Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women.

Cancers·2025

Same author

Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.

Breast (Edinburgh, Scotland)·2025

Same author

Anti-progestin therapy targets hallmarks of breast cancer risk.

Nature·2025

Same author

A randomised controlled trial of short-term Intermittent Energy Restriction [IER] versus Continuous Energy Restriction [CER] on body fat stores and measures of insulin resistance in women with obesity at increased risk of breast cancer.

BMC nutrition·2025

Same journal

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Videos

Selective oestrogen receptor downregulator

Related Concept Videos

How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK family history risk and prevention clinic.

Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancer.

Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women.

Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.

Anti-progestin therapy targets hallmarks of breast cancer risk.

A randomised controlled trial of short-term Intermittent Energy Restriction [IER] versus Continuous Energy Restriction [CER] on body fat stores and measures of insulin resistance in women with obesity at increased risk of breast cancer.

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

Related Experiment Videos

Selective oestrogen receptor downregulator

Related Concept Videos

Related Articles

How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK family history risk and prevention clinic.

Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancer.

Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women.

Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.

Anti-progestin therapy targets hallmarks of breast cancer risk.

A randomised controlled trial of short-term Intermittent Energy Restriction [IER] versus Continuous Energy Restriction [CER] on body fat stores and measures of insulin resistance in women with obesity at increased risk of breast cancer.

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.